Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas

NCT02454634 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
39
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

National Center for Tumor Diseases, Heidelberg

Collaborators